touchNEUROLOGY had the pleasure of meeting with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) and Ralf Reilmann (Founding Director, George Huntington Institute, Münster, Germany), to discuss the clinical utility of pridopidine in Huntington’s disease, and the ongoing PROOF-HD study.
The abstract entitled ‘The PROOF-HD Study: Pridopidine’s Outcome on Function in Huntington Disease’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
- Could you tell us a little about pridopidine and its mechanism of action? (1:00)
- What have clinical studies to date taught us about the clinical utility of pridopidine in Huntington’s disease, and what have been the limitations of these studies? (3:43)
- How have previous data been used to optimise the design of the PROOF-HD trial? (12:41)
Disclosures: Andrew Feigin has served as a consultant for NeuExcell, Prilenia, Stealth, and Voyager. Ralf Reilmann has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
Share this Video
Related Videos In Neurodegenerative Diseases
Rajeev Kumar, MDS 2022: ANX005, a humanized monoclonal antibody for Huntington’s disease, the phase 2 study results
The phase 2 study results of ANX005, a humanized monoclonal antibody targeting C1q, for patients with Huntington’s disease were presented at MDS 2022. In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) to discuss the key results, their significance and the next steps. The abstract entitled […]
Rajeev Kumar, MDS 2022: The role of complement activation in people living with Huntington’s disease
ANX005, a humanized monoclonal antibody, is designed to inhibit the classical complement pathway which has been associated with Huntington’s disease (HD). In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) to discuss the role of complement activation in people living with HD and why ANX005 is […]
Esther Cubo, MDS 2022: Insulin-like growth factor-1 and social cognition in Huntington’s disease
This study in patients with Huntington’s disease aimed to assess insulin-like growth factor-1 (IGF-1) levels and hypothalamic function, and the association with non-motor symptoms and brain structure. In this touchNEUROLOGY interview, we speak with Dr Esther Cubo (Hospital Universitario de Burgos, Burgos, Spain) to discuss the study, its findings and future studies that are planned. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!